What Actually Happens When Women Take GLP-1 Medication? A New Study Has Answers

Most of what you hear about GLP-1 medications like Mounjaro comes from controlled clinical trials. Those trials are carefully designed, but they don't always reflect what happens when real women, with real lives and real schedules, start treatment outside a research setting.

A new study, carried out by SheMed in partnership with University College London and led by Professor John Deanfield, looks at exactly that. It's one of the largest real-world studies of GLP-1 treatment in women ever conducted, following over 8,000 women through SheMed's digital care programme. The study has now been published, and this article reflects the approved findings.

‍

Why real-world data matters here

Clinical trials tell you what a medication can do under ideal conditions. They don't always tell you what happens when people juggle side effects, forget doses, lose motivation, or simply stop attending appointments. In the GLP-1 category specifically, adherence has been one of the biggest real-world challenges. People often start strong and taper off before they see the full benefit.

There's a second gap this study addresses. Large obesity and cardiometabolic trials have tended to enrol mostly men, even though women make up the majority of people using GLP-1 treatment in routine and community care. That's a significant blind spot, and it's a longstanding one. Only 2% of UK medical research funding is spent on pregnancy, childbirth, and female reproductive health [1], and conditions like PMOS, endometriosis, and menopause remain understudied as a result. This study was designed to help close that gap. Every participant, every data point, and every outcome in the dataset is female, making it one of the most comprehensive real-world datasets on GLP-1 treatment in women ever collected.

‍

What the study looked at

Participants were adult women enrolled in SheMed's UK-wide digital programme, which combines:

• Weekly video check-ins with trained clinical staff
• Mandatory monthly health monitoring as a condition of prescription renewal
• Clinician-led, individualised dose adjustments rather than automatic dose escalation
• Structured support for managing side effects throughout treatment

The vast majority of participants were prescribed tirzepatide, the active ingredient in Mounjaro. Outcomes were tracked over a six-month period.

The cohort itself reflects a genuinely real-world population rather than a narrowly selected trial group. Over 8,000 women were enrolled across the UK, ranging in age from 18 to 79 and spanning diverse ethnicities, BMI ranges, and health backgrounds. Average BMI at baseline was 38.2, spanning Obesity classes I to III, which is broadly representative of the women who seek out GLP-1 treatment in everyday practice, not a filtered sample designed to produce the strongest possible results.

‍

‍

What the results show

High retention

Retention at six months was over 90%, a notably strong result for GLP-1 treatment delivered outside a hospital or specialist clinic setting. Adherence has historically been one of the weakest points in real-world GLP-1 use, so sustained engagement at this level is a meaningful finding on its own.

Meaningful weight loss across the group

Weight loss was a consistent outcome across the cohort. Participants achieved an average weight loss of 20%, with women losing an average of 16kg or more within six months. The majority achieved clinically meaningful weight loss, the kind associated with improved long-term health outcomes, and a significant proportion reached transformative levels of weight reduction. Tracked over time, the trajectory of weight loss in the cohort was steeper and more sustained than what's typically reported with diet and exercise alone, reinforcing why structured, clinician-supported treatment matters for long-term results.

Quality of life improvements

The impact went well beyond the number on the scale. 97% of participants reported feeling healthier overall, with significant improvements across the health measures the study tracked. That's a strong signal that the programme's benefits are felt day to day, not just visible in a lab result six months later.

Improvements beyond the scale

Metabolic health improved substantially across the cohort. Among participants who started within the diabetes range, 84% saw their blood sugar levels normalise over the course of treatment, a meaningful marker of improved metabolic health and reduced long-term diabetes and cardiovascular risk.

Heart health

Participants also reported a lower risk profile for cardiovascular health, with improvements in symptoms across a range of female-related conditions. Combined with the metabolic and weight-loss findings, this points to benefits that extend well beyond the primary goal of weight reduction.

Consistent results across different groups of women

Outcomes held steady across age groups, starting weights, and socioeconomic backgrounds, and across the full BMI range represented in the cohort. That consistency matters because it suggests the programme's structure, rather than any single participant characteristic, is driving the results. It also matters for a different reason: it shows the approach works for the kind of diverse, real-world population that's historically been left out of obesity research, not just for a narrow subset of women who were always likely to respond well.

Personalised dosing, not maximum dosing

One of the more notable findings is that strong outcomes were achieved without requiring every participant to reach the highest available dose. Dosing was adjusted individually based on clinical response, rather than following a fixed escalation schedule. This challenges a common assumption in the GLP-1 category, that maximum dosing is necessary for meaningful results.

No serious safety concerns

No serious treatment-related adverse events were identified across the cohort.

‍

‍

‍

‍What this means if you're considering GLP-1 treatment

If you've been weighing up whether a digitally delivered programme can offer the same level of oversight as in-person care, this study is a useful data point. It suggests that with the right structure, weekly clinical contact, mandatory monitoring, and individualised dosing, a remote programme can support the kind of consistent engagement that drives real results.

It's also a reminder that dose escalation isn't the only lever for success. Personalised, clinician-guided titration appears to support both effectiveness and tolerability, which may help more women stay on treatment long enough to see meaningful change.

And for anyone who's felt like existing weight loss research doesn't reflect their own body or circumstances, this study is a step toward closing that gap. With over 8,000 women, spanning ages 18 to 79 and a wide range of BMIs, ethnicities, and health backgrounds, the results reflect what's genuinely achievable across a broad population of women, not a narrow trial cohort selected to produce the best possible headline.

‍

Frequently Asked Questions

What medication did most participants in the study take?

The large majority of participants were prescribed tirzepatide, the active ingredient in Mounjaro, as part of SheMed's clinician-led programme.

How long did the study track participants?

Outcomes were followed over a six-month period from the start of treatment.

Is the study published yet?

Yes. The study has been published, and this article reflects its approved findings. We'll continue to update this page as more detail from the paper becomes available.

Did the study include a comparison group?

This is a real-world observational study, not a randomised controlled trial, so it doesn't include a direct comparison group. It's designed to show what happens under typical, real-world conditions rather than in a controlled trial setting.

Were there any safety concerns?

No serious treatment-related adverse events were identified among participants in the study.

How does this study reflect real-world women, rather than a selected trial group?

The cohort included over 8,000 women aged 18 to 79, spanning diverse ethnicities and health backgrounds, with an average baseline BMI of 38.2 across Obesity classes I to III. This is broadly representative of the women who seek out GLP-1 treatment in everyday practice.

‍

References

"Digital-first delivery of GLP-1 receptor agonist therapy in a large real-world cohort of women," Deanfield J, et al. Conducted in partnership with University College London. [Link to be added once the published version and DOI are confirmed.]

[1] UK research funding statistic on pregnancy, childbirth, and female reproductive health. [Source to be added, matching the citation used on SheMed's clinical results page.]

‍